Memorial Sloan Kettering Cancer Center
New York, NY
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
BTX-A51
A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Kinase Inhibitor
- Phase 1
- Has results
Accepting patients
FHD-286
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Learn more- BRG1 Inhibitor
- BRM Inhibitor
- Phase 1
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Learn more- NLRP3 Inhibitor
- Phase 1
Accepting patients
SGR-2921
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Learn more- CDC7 Inhibitor
- Phase 1
Accepting patients
GLB-100
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- High Risk
- Phase 1
Accepting patients
KT-253
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
Learn more- MDM2 Inhibitor
- Phase 1
Accepting patients
REM-422
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Learn more- MYB mRNA Degrader
- Phase 1
Accepting patients
Cord Blood Transplant
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Learn more- Cord Blood
- Phase 2
Accepting patients
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Phase 2